Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Strontium chloride Sr-89 is a radiopharmaceutical agent used for the relief of bone pain in patients with painful skeletal metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.
- Mechanism
- Curator reviewed · 2 references
Strontium chloride 89, a similar to calcium divalent ion, concentrates in areas of increased osteogenesis, by being taken up into the inorganic matter of the bone. Strontium chloride 89 presents a 10-fold higher affinity for metastatic bone. Some reports indicate that after Strontium chloride 89 is incorporated into the osteoid matrix adjascently to the metastatic cells, it emits β-rays getting even to 1.3-64Gy. Thus, there is a possible tumoricidal effect driven by the radiation selectively emited by strontium chloride 89 into metastatic bones.
- Primary indication
- Strontium-89 Chloride Injection is indicated as a paliative for the relief of bone pain in patients with skeletal metastases.Curator reviewed · 1 structured indication
- Formula / weight
- Cl2Sr · 159.81 g/mol (avg)
- First approval
- United States, 1993
- Also known as
- Strontium (89Sr) chloride · Strontium chloride Sr 89 · Strontium chloride, Sr-89 · Strontium-89 chloride
- Code names
- SMS-2PA
Resolves to
AHBGXTDRMVNFER-FCHARDOESA-LSMILES[Cl-].[Cl-].[89Sr++]What you can answer from here — as of July 14, 2025
Which other approved drugs treat the same conditions as Strontium chloride Sr-89, and which companies have late-stage candidates in those indications?